Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03164603 · ClinicalTrials.gov registry record · Phase 1
NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors
A Phase 1 study, sponsored by NewLink Genetics Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT03164603 is a Phase 1 study that has completed, run by NewLink Genetics Corporation. The registered enrollment target is 26 participants.
The verdict
NCT03164603, a Phase 1 study, has completed, sponsored by NewLink Genetics Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This is an open-label Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of NLG802, an investigational agent intended to inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme and help the human immune system attack solid tumor cells more effectively.
Interventions
- DRUG NLG802
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2017-06-29 |
| Est. Completion | 2019-09-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03164603
The ClinicalTrials.gov registry entry for NCT03164603 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NewLink Genetics Corporation, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NLG802 is the first listed.
NCT03164603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03164603 about?
NCT03164603 is a clinical study titled "NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors". This is an open-label Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of NLG802, an investigational agent intended to inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme and help the human immune system attack solid tumor cells more effectively.
What is the current status of trial NCT03164603?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2017-06-29. Estimated completion is 2019-09-25.
What interventions are being tested in trial NCT03164603?
The interventions under investigation include: NLG802 (DRUG).
Who is sponsoring clinical trial NCT03164603?
This trial is sponsored by NewLink Genetics Corporation, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.